Catalent Biologics Content
-
Catalent Capabilities Update June 2026: Cell Line Development
6/24/2026
Discover how an integrated approach to transient expression, cell line development, and manufacturing can accelerate biologics development from gene to IND.
-
Accelerating Antibody Development: A Proven Path From Gene To GMP
6/5/2026
Discover how an optimized, end-to-end development strategy can help sponsors reach key clinical milestones faster and bring potentially life-saving therapies to patients sooner.
-
GPEx® Lightning: Stable Cell Line Development For Complex Biologics
6/5/2026
GPEx® Lightning delivers stable cell pools in 25 days, titers exceeding 15g/L for mAbs and 11g/L for bispecifics, and 60+ generations of stability — compressing timelines by 6–12 weeks.
-
Madison: Clinical, Commercial Drug Substance Development
6/2/2026
Catalent Madison offers gene-to-GMP drug substance in 8 months via GPEx Lightning CHO cell lines, hitting 15+ g/L, backed by 24 approved products and 5 GMP trains up to 4,000 L.
-
Unlock The Potential Of GPEx® Lightning: Accelerate Your HEK Cell Line Development
5/8/2026
Cut HEK cell line development to four months with 30% higher titers. GPEx® Lightning delivers faster, scalable biologics manufacturing. Access the full summary now.
-
The Growing Strategic Importance Of CDMOs In CGT
5/8/2026
Discover how advanced manufacturing platforms, integrated analytics, and accelerated development strategies are helping overcome the scalability, supply chain, and operational challenges.
-
Data-Driven Manufacturing And Case Management In Autologous Cell Therapy
3/25/2026
Explore how data-driven manufacturing and end-to-end supply chain orchestration can help cell therapy developers overcome manufacturing challenges, reduce costs, and scale programs more effectively.
-
Catalent Capabilities Update March 2026: Analytical Services
3/24/2026
A biologics analytics leader showcases development, testing, and characterization capabilities, emphasizing quality, regulatory compliance, and integrated support from discovery to commercialization.
-
Critical Path For Gene Therapy: AAV Analytical Lifecycle Considerations
12/2/2025
Explore considerations for phase-appropriate AAV characterization and release activities from pre-clinical to late-phase products. Review validation challenges and paths for maturation of analytics.
-
Advanced iPSC Workflows: Accelerating Cell Therapy Development
9/30/2025
Beyond offering our GMP-compliant iPS cells, we develop superior workflows for gene editing and differentiation to provide competitive platforms to our partners and accelerate their therapeutic programs.